PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Elsevier Backs Pistoia Alliance for AI in Drug Discovery

New initiatives to tackle AI-related challenges in life sciences.

Elsevier, a leader in information and analytics, has announced its support for The Pistoia Alliance in promoting safe and responsible AI adoption in drug discovery.

This effort aims to address key AI challenges, including the need for trustworthy data and AI transparency, through industry workshops, webinars, and conferences.

Elsevier’s commitment will provide expertise to over 200 member organisations of Pistoia, including major pharmaceutical, biotech, healthcare, and R&D firms.

This partnership has been ongoing for over a decade, focusing on equipping the industry with tools for effective, safe, and ethical AI usage in drug discovery.

Mirit Eldor, Managing Director, Life Sciences Solutions at Elsevier, stated, “The Pistoia Alliance continues to be the ideal forum for productive collaboration. Coming together to share learnings can help overcome data barriers in life sciences.”

The announcement follows Elsevier’s recent Attitudes to AI report, highlighting both enthusiasm and concern among researchers regarding AI use.

Common issues include misinformation, critical errors, and gaps in critical thinking, as mirrored in Pistoia’s Lab of the Future Report. Both reports underscore the need for better educational resources, such as ontologies training.

Elsevier has pinpointed five key areas to drive AI adoption in drug discovery: securing trustworthy data, structuring data for insights, ensuring transparent AI, unified governance, and bridging the skills gap.

Dr Becky Upton, President of the Pistoia Alliance, said, “Elsevier’s and our surveys show researchers are eager to adopt AI but face challenges with data access and trust. Elsevier has been a valued member since 2015, contributing to initiatives shaping our industry’s future.”

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026